Objective In neuromyelitis optica (NMO), the destruction of the blood–brain barrier (BBB) has been considered to be the first step of the disease process. It is unclear whether sera from patients with NMO can open the BBB, and which component of patient sera is most important for this disruption.
Methods The effects of sera from antiaquaporin4 (AQP4) antibody positive NMO patients, multiple sclerosis patients and control subjects were evaluated for expression of tight junction proteins and for transendothelial electrical resistance (TEER) of human brain microvascular endothelial cells (BMECs). Whether antibodies against human BMECs as well as anti-AQP4 antibodies exist in NMO sera was also examined using western blot analysis.
Results Expression of tight junction proteins and TEER in BMECs was significantly decreased after exposure to NMO sera. However, this effect was reversed after application of an antivascular endothelial growth factor (VEGF) neutralising antibody. Antibodies against BMECs other than anti-AQP4 antibodies were found in the sera of NMO patients whereas no specific bands were detected in the sera of healthy and neurological controls. These antibodies apparently disrupt the BBB by increasing the autocrine secretion of VEGF by BMECs themselves. Absorption of the anti-AQP4 antibody by AQP4 transfected astrocytes reduced AQP4 antibody titres but was not associated with a reduction in BBB disruption.
Conclusions Sera from NMO patients reduce expression of tight junction proteins and disrupt the BBB. Autoantibodies against BMECs other than anti-AQP4 antibodies may disrupt the BBB through upregulation of VEGF in BMECs.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Neuromyelitis optica (NMO) is defined as an inflammatory CNS disease predominantly affecting the spinal cord and the optic nerves.1 This disorder was long regarded as a variant of multiple sclerosis (MS), with distinctive pathological features.2 A breakthrough in our understanding of NMO was identification of an autoantibody response with high sensitivity and specificity for the disease, which was found to be directed against the astrocytic water channel aquaporin 4 (AQP4).3 Several studies have suggested that the anti-AQP4 antibody is pathogenic and it also plays a key role in the development of NMO.4–11
Circulating anti-AQP4 antibodies need to pass through the blood–brain barrier (BBB) in order to reach the CNS parenchyma, which is the site affected by inflammation in this disease. Initiation of disease by transfer of these antibodies into normal animals has not been achieved to date12 because the BBB restricts the entry of circulating anti-AQP4 antibodies into the CNS under normal conditions. Although destruction of the BBB causing leakage of anti-AQP4 antibodies and cytokines into the CNS space has been considered as a key step in the development of NMO, it remains unclear which components of patient sera is most important for disruption of the BBB. It is also unclear whether sera from an NMO patient containing circulating anti-AQP4 antibodies can open the BBB because no direct evidence has been presented indicating that the brain microvascular endothelial cells (BMECs), which comprise the BBB, express the AQP4 protein.13 14 Various circulating inflammatory cytokines, including tumour necrosis factor α (TNFα) and vascular endothelial growth factor (VEGF), which have already been reported to induce disruption of the BBB, may be the candidate molecules leading to the breakdown of the BBB.15 16 The existence of unknown pathogenic antibodies, apart from anti-AQP4 antibodies, may also cause BBB impairment.
The aim of the current study was to demonstrate the effects of sera from patients with NMO on impairment of BBB function and to clarify the roles of humoral factors, especially antibodies, against human BMECs, in the destruction of the BBB.
Materials and methods
Sera and antibody
The acute phase sera from 14 consecutive NMO patients hospitalised at our institution were studied. All patients met the clinical criteria for NMO spectrum disorders.17 18 None of the NMO patients had antinuclear antibodies or SS-A/SS-B antibodies. The human anti-AQP4 antibody was detected in all patients by a procedure previously described by Takahashi.9 Blood samples were obtained within 7 days of onset and stored at −80°C until use. The sera from two patients who began plasma exchange (PE) treatment were also obtained. The acute phase sera from seven patients with conventional MS (C-MS), diagnosed by the McDonald criteria,19 were also used in this study. The sera from 15 patients with autoimmune inflammatory neurological diseases, including three patients with neuropsychiatric systemic lupus erythematosus (NP-SLE), four patients with dermatomyositis, three patients with myasthenia gravis, three patients with multifocal motor neuropathy and two patients with microscopic polyangiitis were studied as inflammatory disease controls. All NP-SLE, dermatomyositis and microscopic polyangiitis patients had antinuclear antibodies. In contrast, none of the myasthenia gravis and multifocal motor neuropathy patients had these antibodies. Sera from 12 patients with non-inflammatory neurological diseases, including four patients with amyotrophic lateral sclerosis, two patients with Parkinson's disease, four patients with cervical spondylosis and two patients with multiple system atrophy, were used as neurological disease controls. The sera from 12 healthy individuals also served as normal controls. All sera were incubated at 65○C for 30 min just prior to use. There were no statistically significant differences in the concentrations of IgG between the serum samples of the 14 NMO, 7 MS and 12 normal controls (means±SEM, NMO 1035±517 mg/dl; MS 1090±151 mg/dl; normal controls 1042±225 mg/dl) when the concentration of IgG in each of the samples was measured. The use of the patient's sera for this study was approved by the ethics committee of Yamaguchi University following the principles of the Declaration of Helsinki.
Cell culture and treatment
The immortalised human brain microvascular endothelial cells (BMECs) were generated previously.20 Briefly, we previously established conditionally immortalised BBB derived endothelial cells, called TY08 cells, harbouring the temperature sensitive SV40 large T antigen (tsA58) protein.20 The gene product of tsA58 is in an active conformation and binds to p53 at 33°C, thus facilitating the immortalisation of the cells, whereas the conformation of the gene product changes, leading to its degradation and the release of p53 when the cells are grown at 37°C. Therefore, these cells are conditionally immortal. The cells expressed all key tight junctional proteins, such as occludin, claudin-5, ZO-1 and ZO-2, and had low permeabiltity to inulin across monolayers. All of the analyses were determined 3 days after the temperature shift from 33°C to 37°C. Human umblilical vein endothelial cells (HUVECs), human fibroblasts and 293T cells were obtained from the Japan Health Sciences Foundation (Osaka, Japan) and human astrocytes were purchased from Lonza (Walkersville, Maryland, USA). BMECs were treated with culture medium containing 10% patient or healthy control sera in a humidified atmosphere of 5% CO2/air. BMECs treated with culture medium with 10% fetal bovine serum (Sigma, St. Louis, Missouri, USA) were used as controls. The mRNAs were extracted 24 h later, and total proteins were obtained a day later.
The culture medium for BMECs consisted of Dulbecco's modified Eagle's medium (DMEM; Sigma) containing 100 U/ml penicillin (Sigma), 100 μg/ml streptomycin (Sigma), 25 ng/ml amphotericin B (Invitrogen, Grand Island, New York, USA) and 10% fetal bovine serum (Sigma). Polyclonal anticlaudin-5 and antioccludin antibodies were purchased from Zymed (San Francisco, California, USA). The polyclonal antiactin antibody was obtained from Santa Cruz (Santa Cruz, California, USA). The polyclonal antitransforming growth factor β (TGFβ), anti-VEGF, anti-interleukin (IL)-6, anti-IL-17, anti-interferon γ (IFNγ) and anti-TNFα antibodies were purchased from R&D systems (Minneapolis, Minnesota, USA). Lysates of human claudin-5 transfected 293T cells and control 293T cells were purchased from Santa Cruz. A total of 5 μg of protein lysates were loaded for the western blot analysis.
Quantitative real time PCR analysis
Total RNA was extracted from BMECs using an RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Single stranded cDNA was created from 40 ng of total RNA using the StrataScript First Strand Synthesis System (Stratagene, Cedar Greek, Texas, USA.). The sequence of each human primer pair and its reference are as follows: sense primer 5′-CTG TTT CCA TAG GCA GAG CG-3′ and antisense primer 5′-AAG CAG ATT CTT AGC CTT CC-3′ for claudin-521; sense primer 5′-TGG GAG TGA ACC CAA CTG CT-3′ and antisense primer 5′-CTT CAG GAA CCG GCG TGG AT-3′ for occludin22; and sense primer 5′-GTC AAC GGA TTT GGT CTG TAT T-3′ and antisense primer 5′-AGT CTT CTG GGT GGC AGT GAT-3′ for glyceraldehyde-3-phosphate dehydrogenase.23 Quantitative real time PCR analyses were performed using a Stratagene Mx3005P (Stratagene) with FullVelocity SYBR Green QPCR master mix (Stratagene). Glyceraldehyde-3-phosphate dehydrogenase was used as an internal standard. The samples were subjected to PCR analysis using the following cycling parameters: 10 min at 95°C followed by 40 cycles for 15 s at 95°C, 1 min at 60°C and 1 min at 72°C. The standard reaction curve was analysed by the MxPro (Stratagene) software programme and the relative quantity according to standard reaction curve (Rv) was calculated by computer according to the formula Rv=RGene/RGAPDH.
Western blot analysis
Protein samples (10–20 μg) were separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (Biorad, Hercules, CA, USA) and transferred to nitrocellulose membranes (Amersham, Chalfont, UK). Expression of β-actin was used as an internal standard. The membranes were treated with blocking buffer (5% skimmed milk in 25 mM Tris-HCl, pH 7.6,125 nM NaCl, 0.5% Tween 20) for 1 h at room temperature and incubated with the relevant primary antibodies (dilution 1:100) for 2 h at room temperature. The membranes were then exposed to a peroxidase conjugated secondary antibody (1:2000), followed by a chemiluminescence reagent (Amersham), and exposure to X-Omat S films (Amersham) and quantification of the band intensity was obtained using the Fuji image analysis software package.
Cultured cells were fixed with 4% paraformaldehyde (Wako, Osaka, Japan) and permeabilised with 100% methanol. Cells were subsequently incubated overnight with 5% serum (as relevant primary antibodies (dilution 1:20)) and then were incubated with a FITC labelled secondary antibody at a dilution of 1:200 for staining. Fluorescence was observed by a fluorescence microscope (Olympus, Tokyo, Japan). The nuclei were stained with DAPI, and the fluorescence was detected with a fluorescence microscope (Olympus). Image stacks were analysed with the localisation module of the Olympus software program (Olympus).
Transendothelial electrical resistance studies
Transwell inserts (pore size 0.4 μm, effective growth area 0.3 cm2, BD Bioscience, Sparks, Maryland, USA) were coated with rat tail collagen type I (BD Bioscience). Transendothelial electrical resistance (TEER) values of cell layers were measured with a Millicell electrical resistance apparatus (Endohm-6 and EVOM; World Precision Instruments, Sarasota, Florida, USA). BMECs were seeded (1×106 cells/insert) on the upper compartment and incubated with each medium (non-conditioned medium used as a control, conditioned medium contained 10% patient sera) for 24 h.
Studies with patient sera preincubated with neutralising antibodies against TNFα, IFNγ, VEGF, TGFβ, IL-6 or IL-17
BMECs were incubated with the sera from eight NMO patients containing 2.0 μg/ml of a neutralising antibody against TNFα, IFNγ, VEGF, TGFβ, IL-6 or IL-17, or normal rabbit IgG. Total RNA was extracted and the TEER value was measured 24 h later. Total proteins were obtained the next day.
Sera from NMO patients were pretreated with 2.0 μg/ml of a neutralising antibody against TNFα, IFNγ, VEGF, TGFβ, IL-6 or IL-17, or normal rabbit IgG (control antibody) for 6 h at 4°C. BMECs were cultured with the sera from eight NMO patients containing each neutralising antibody at 37°C. Total RNA was extracted and the TEER value was measured 24 h later. Total proteins were obtained the next day.
Absorption of the anti-AQP4 antibody by AQP4 transfected cells
Human astrocytes were transfected with a retrovirus incorporating the shorter isoform of human AQP4 (M-23) in order to overexpress the AQP4 protein. Expression of the AQP4 protein in astrocytes was verified by western blot analysis. Sera from two NMO patients were added to the transfected cells. After a 30 min incubation period at 37°C in 5% CO2 with gentle shaking, the patients' sera were removed and used for the subsequent analyses. This process was repeated at least five times (total exposure time 150 min).
Unless otherwise indicated, all data represent means±SEM. An unpaired two-tailed Student t test was used to determine the significance of differences between the means of two groups. A p value of <0.05 was considered to be statistically significant.
Sera from patients with NMO reduced the expression of tight junction molecules in BMECs
To analyse whether the sera from NMO patients affects the BBB, we first examined the effect of sera from patients with NMO or C-MS on BMECs. The amount of claudin-5 in BMECs was significantly decreased after exposure to sera from patients with NMO whereas it was not affected by the sera from patients with C-MS or from healthy controls, as determined by a western blot analysis (figure 1A,D). Expression levels of occludin and the ZO-1 protein were not significantly influenced by the application of sera from patients with NMO, C-MS or from healthy controls (figure 1B,C,E,F). The TEER value of BMECs was significantly decreased after exposure to sera from patients with NMO although it was not changed by incubation with sera from patients with C-MS or from healthy controls (figure 1G).
Anti-BMEC antibodies were present in the sera from NMO patients, and plasmapheresis reduced the ability of sera from NMO patients to disrupt the BBB
Next we analysed whether autoantibodies against human BMECs were present in the sera of NMO patients by a western blot analysis. Antibodies that bound to both BEMCs and astrocytes were seen in the sera from 10 of 14 NMO patients (71.4%) and three of seven C-MS patients (42%) (figure 2A), but no protein bands against human fibroblasts or 293T cells (as negative controls) were detected in the sera from any of the NMO patients (figure 2A). No protein bands were demonstrated in the sera from any of the 14 patients with autoimmune inflammatory neurological diseases, from the 11 non-inflammatory neurological controls or from the 12 healthy control serum samples (data not shown) although anti-BMEC antibodies were present in the sera of one NP-SLE patient. The sera from NMO patients predominantly reacted with one or more antigens of approximately 35, 60, 80 and 110 kDa in both BMECs and astrocytes (figure 2A). The 60 kDa bands in BMECs and astrocytes were commonly detected in all NMO patients but sera from some NMO cases also showed antibodies against the 60 kDa antigens in HUVECs. The bands corresponding to the 35 and 110 kDa antigens of BMECs were specific in BMECs and astrocytes, and were not detected in HUVECs. The 80 kDa bands in BMECs, HUVECs and astrocytes were commonly detected in NMO patients although the sera from NP-SLE patients also reacted with 80 kDa antigens from both HUVECs and BMECs (figure 2A). Serum samples from patients with C-MS reacted with approximately 32, 38, 60 and 110 kDa antigens of BMECs (figure 2A). Notably, antibodies against the antigens corresponding to 32 and 38 kDa were specific for MS patients and were not seen in NMO patients. We next examined whether anticlaudin-5 antibodies were present in the sera of NMO patients by western blot analysis. No protein bands corresponding to anticlaudin-5 antibodies were demonstrated in any of the NMO sera by immunoblotting of the whole cell lysates prepared from 293T cells with or without transfection of the human claudin-5 gene (figure 2B). Immunocytochemical analysis also showed that the anti-BMECs antibodies in NMO sera were localised in the cytoplasm of BMECs, thus showing a granular pattern (figure 2C–G). Furthermore, PE treatment reduced the titres of the anti-AQP4 antibodies (figure 2H) and led to an increase in the expression of claudin-5, and an increase in TEER values in BMECs, suggesting that the removal of anti-BMEC antibodies or anti-AQP4 antibodies decreased the ability of sera from NMO patients to disrupt the BBB (figure 2I–K). The effects on claudin-5 and TEER values in NMO patient No 1 seemed almost the same as those in NMO patient No 2 who had high titres of anti-AQP4 antibodies although AQP4 antibody titre in patient No 1 was very low (1:8) and the reduction to 1:4 after PE was not significant, suggesting that the effect of NMO sera to BBB disruption was not due to anti-AQP4 antibodies but other factors in the serum constituents (figure 2H–K).
VEGF in NMO sera disrupted the BBB
Various circulating inflammatory cytokines may be candidate agents disrupting the BBB. To clarify the contribution of inflammatory cytokines to BBB breakdown, TNFα, IL-6, IFNγ, IL-17, VEGF and TGFβ activities were neutralised using the corresponding neutralising antibodies. Expression of claudin-5 or occludin mRNA in BMECs increased after exposure to NMO sera pretreated with the anti-VEGF or IL-17 neutralising antibodies, as determined by relative quantification with a real time RT-PCR analysis (figure 3A). We classified the sera of the eight NMO patients into two different groups: five with anti-BMEC antibodies (group 1) and three without anti-BMEC antibodies (group 2) (figure 3B,C). Expression of claudin-5 or occludin mRNA in BMECs was significantly increased by preincubation with an anti-VEGF antibody or an anti-IL-17 antibody in group 1 NMO sera (figure 3B). In contrast, pretreatment with an anti-IL-17 antibody significantly increased expression levels of occludin mRNA in group 2 NMO sera although pretreatment with the anti-VEGF antibody did not influence expression in that group (figure 3C). Next, changes in claudin-5 and occludin protein levels in BMECs after exposure to group 1 NMO sera pretreated with anti-VEGF or IL-17 antibodies were determined by western blot analysis (figure 3D). After confirming the effects seen at the mRNA level, expression of claudin-5 in BMECs significantly increased after preincubation with anti-VEGF antibodies whereas it did not change after preincubation with anti-IL-17 antibodies (figure 3D). The TEER value of the BMECs was also significantly increased after exposure to the group 1 NMO sera pretreated with an anti-VEGF antibody but was not affected after anti-IL-17 antibody pretreatment (figure 3E).
Anti-BMEC antibodies in NMO sera disrupted the BBB through upregulation of autocrine VEGF in BMECs
The concentration of VEGF was not significantly different between the sera from NMO patients and from healthy controls, as determined using ELISA (figure 4A). We thus hypothesised that anti-BMEC antibodies may disrupt the BBB by increasing the autocrine secretion of VEGF in BMECs. Expression of VEGF in BMECs was significantly increased after exposure to sera from group 1 NMO patients with anti-BMEC antibodies although it did not change after exposure to sera from group 2 NMO patients without anti-BMEC antibodies, or after sera from C-MS patients or healthy controls (figure 4B,C). Expression of VEGF secreted by astrocytes and HUVECs did not change after exposure to the sera of NMO patients (figure 4D).
Reduction of the anti-AQP4 antibody titre did not influence the ability of sera from NMO patients to disrupt the BBB
The 30 kDa single band corresponding to the shorter isoform of the AQP4 protein (AQP4-M23) was detected in BMECs by western blot analysis (figure 5A). We next examined whether anti-AQP4 antibodies in NMO sera were indeed responsible for disruption of the BBB. For this purpose, we preabsorbed anti-AQP4 antibodies from the sera of two different NMO patients using human astrocytes expressing human AQP4. These cells were generated via transduction with a retrovirus incorporated shorter isoform of the human AQP4 gene (M-23) into immortalised human astrocytes. The method used in our study can absorb not only anti-AQP4 antibodies but also other antibodies that react with the cell surfaces antigens expressed by astrocytes. In both patients, the titres of the anti-AQP4 antibodies from NMO sera were decreased to one half or less than that of unadsorbed antibodies after a 150 min incubation period with the astrocytes although there was no significant change after a 30 min incubation period (figure 5B). Both the sera with and without reduction of the anti-AQP4 antibodies led to an increase in the expression of claudin-5 and in the TEER values of BMECs (figure 5C–E), suggesting that a reduction in anti-AQP4 antibody titre did not influence the ability of NMO sera to disrupt the BBB.
In this study, we used our established conditionally immortalised BBB derived endothelial cells to analyse the effects of sera from patients with NMO on impairment of BBB function. Although it would have been better to elucidate barrier function using microvascular endothelial cells derived from the spinal cord and optic nerve, no optimal endothelial cell lines originating from the spinal cord or optic nerve have been developed to date in any laboratory due to the difficulty in isolating a sufficient amount of microvascular endothelial cells from a minuscule amount of spinal cord and optic nerve tissue. We believe it was reasonable to use BMECs because several studies have shown a high incidence of brain lesions in approximately 60% of patients with NMO.24 25 It is unclear why NMO predominantly affects the spinal cord and optic nerves despite the fact that destruction of the BBB occurs in NMO, but one possibility may be that the barrier properties of the microvascular endothelial cells derived from the spinal cord and optic nerve are more leaky than those of the BBB and, as a result, the destruction of barrier property causes more leakage of the anti-AQP4 antibodies and cytokines into the spinal cord and optic nerve spaces.
Several lines of evidence suggest that the bulk of the anti-AQP4 antibody is synthesised in the peripheral lymphoid compartment in affected individuals.9 The anti-AQP4 antibody contained in the sera of NMO patients did not induce NMO-like lesions when injected into normal rats but did cause disease in experimental animals with T cell mediated brain inflammation.12 This indicates that a leaky BBB that allows the intrusion of circulating anti-AQP4 antibodies thus plays a crucial role in the development of NMO. However, the molecular mechanism of BBB breakdown in NMO has not been adequately explained. Our present study is the first to demonstrate that sera from patients with NMO can open the BBB. Expression of tight junction proteins and TEER value in BMECs was significantly decreased after exposure to sera from patients with NMO. Together, these results indicate that humoral factors in NMO sera disrupt the BBB; we therefore first tried to identify the most important substance involved in opening the BBB in NMO patients.
Antiendothelial cell (EC) antibodies binding to HUVECs have been detected in patients with several autoimmune diseases, such as SLE and MS.26–29 Several studies demonstrated that anti-EC antibodies containing SLE sera activated ECs and facilitated the recruitment and trafficking of leucocytes into the inflamed vessels by increasing the expression of adhesion molecules and proinflammatory cytokines, including E-selectin and intercellular adhesion molecule 1, IL-1, TNFα and VEGF in an autocrine or paracrine manner.30–37 No anti-EC antibodies have been detected in the sera from NMO patient to date but some reports have demonstrated that these may be a marker of disease activity in MS.28 Therefore, based on this information and the fact that anti-AQP4 antibodies were insufficient to induce NMO lesions in the absence of inflammation, we hypothesised that anti-BMEC antibodies other than the anti-AQP4 antibodies might be involved in causing BBB disruption in NMO patients. Our study demonstrated that anti-BMEC antibodies were present in the sera of 10 of 14 NMO patients (71.4%) whereas no specific bands were detected in the sera from healthy or neurological disease controls. In contrast, anti-BMEC antibodies were present in the sera from one of three NP-SLE patients but several studies demonstrated that anti-EC antibodies binding to HUVECs have been detected in patients with NP-SLE. Immunocytochemical analysis showed that the anti-BMEC antibodies in NMO sera were localised in the cytoplasm of BMECs showing a granular pattern, similar to anti-EC antibodies in NP-SLE patients, thus suggesting that the anti-BMEC antibodies present in NMO sera as well as NP-SLE sera might contribute to the pathogenesis of BBB breakdown.
The presence of circulating cytokines, including TNFα, IL-6, IFNγ, IL-17A, VEGF and TGFβ, appears to be linked to the pathogenesis of BBB breakdown in NMO patients. Recent data suggest that these cytokines can disrupt the BBB15 16 38–40; in particular, VEGF was able to induce BBB impairment.16 Our present study demonstrated that BBB function was restored after adding a neutralising anti-VEGF antibody to NMO sera, indicating that VEGF was the key molecule responsible for disruption of the BBB in NMO patients. Although concentration of VEGF in sera from NMO patients was not increased compared with sera from healthy control, secretion of VEGF in BMECs was increased after exposure to NMO sera in an autocrine manner. This suggests that anti-BMECs antibodies in sera from NMO patients activated BMECs and stimulated the secretion of VEGF by BMECs themselves, thus causing disruption of the BBB by reducing the production of claudin-5 by BMECs. We speculate that serum levels of VEGF were not increased because VEGF released by BMECs was not sufficiently high to increase serum concentrations but was still enough to influence BMECs by increasing local concentration.
Our study also provides confirmation that the anti-AQP4 antibody is one of the key mediators of BBB impairment in NMO patients because this study was the first to demonstrate that the AQP4 protein was expressed in BMECs using western blot analysis. However, while this antibody may have a role, it appears to be less important that the effects of VEGF or other anti-BMEC antibodies because reduction of the amount of anti-AQP4 antibody after exposure to transfected astrocytes did not influence the ability of sera from NMO patients to induce BBB disruption. Furthermore, we observed that the TEER value and expression of claudin-5 in BMECs were both increased after PE treatment. Removal of humoral factors, including various proinflammatory cytokines as well as presumed antibodies, is now the best explanation for the therapeutic effect following PE in NMO patients.9 10 Removal of these serum constituents, including anti-BMEC antibodies, also restored BBB integrity, providing an additional rationale for PE during the acute stage of NMO. Therapy directed specifically towards BBB repair in the acute stage might also be a promising therapeutic strategy for NMO.
In conclusion, the present study demonstrated that anti-BMEC antibodies in the sera from NMO patients disrupted the BBB through upregulation of VEGF secreted by BMECs. These data provide new pathological explanations concerning the triggers for BBB breakdown and trafficking of anti-AQP4 antibodies into the CNS in the acute stage of NMO. Further studies of the pathological processes underlying NMO lesion formation should help in the development of therapies for this severe and disabling disease.
Funding This work was supported by research grants (Nos 22790821 and 21390268) from the Japan Society for the Promotion of Science, Tokyo, Japan and also by a research grant (K2002528) from Health and Labour Sciences Research Grants for research on intractable diseases (Neuroimmunological Disease Research Committee) from the Ministry of Health, Labour and Welfare of Japan.
Competing interests None.
Ethics approval The study was approved by the ethics committee of Yamaguchi University.
Provenance and peer review Not commissioned; externally peer reviewed.